Buspirone Treatment for Marijuana Dependence

Completed · Phase 4 · Has a placebo group

Conditions studied: Marijuana Dependence

In brief

Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy of buspirone for reducing marijuana use in marijuana-dependent adults. A contingency management (CM) intervention and motivational enhancement therapy (MET) will be incorporated to encourage study engagement and retention. It is hypothesized that buspirone combined with MET and CM will reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent individuals as compared to a placebo treatment combined with MET and CM.

Key facts

Study ID

NCT00875836

Run by

Medical University of South Carolina

People needed

175

Starts

2009-09-01

Expected to finish

2016-03-01

Last updated by the study team

2016-08-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must meet DSM-IV criteria for marijuana dependence.
• Must be between the ages of 18 and 65 years.
• If female and of childbearing potential, must agree to use acceptable methods of birth control for the duration of the trial.
• Must consent to random assignment, and be willing to commit to psychosocial behavioral and medication treatment.
• Must be able to read and provide informed consent.

You may not qualify if…

• Women who are pregnant, nursing, or plan to become pregnant during the course of the study.
• Must not have a history of or current psychotic disorder, bipolar disorder, or eating disorder.
• Must not pose a current suicidal or homicidal risk.
• Must not meet current criteria for major depression.
• Must not have evidence or history of serious hematologic, endocrine, cardiovascular, pulmonary, renal, gastrointestinal or neurologic disease.
• Must not require concomitant therapy with psychotropic medication.
• Must not be currently dependent on other substances, with the exception of nicotine or caffeine.
• Hypersensitivity to buspirone or any other product component.
• Patients who, in the investigator's opinion, would be unable to comply with study procedures or assessments, or would be unacceptable study candidates (e.g., poses threat to staff).

Where it is running

• Medical University of South Carolina — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.